<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110771">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677065</url>
  </required_header>
  <id_info>
    <org_study_id>B4531007</org_study_id>
    <secondary_id>ALO-02 Bioavailability Study</secondary_id>
    <nct_id>NCT01677065</nct_id>
  </id_info>
  <brief_title>A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Single-dose, Randomized, Two-way Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the bioavailability of the controlled-release test formulation is at
      least as high as that for the commercial reference drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serial sampling of venous blood
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Crossover, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>pharmacokinetic endpoints - area under the concentration curve (AUC)</measure>
    <time_frame>0-48 hr</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak concentration (Cmax) and time to peak concentration (Tmax)</measure>
    <time_frame>0-48 hr</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <description>Controlled release oxycodone test formulation 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <description>Immediate release oxycodone reference drug 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone controlled-release test formulation</intervention_name>
    <description>single dose administration of test formulation under fasted conditions</description>
    <arm_group_label>Treatment A</arm_group_label>
    <other_name>ALO-02</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate-release reference drug</intervention_name>
    <description>single dose administration of reference drug under fasted conditions</description>
    <arm_group_label>Treatment B</arm_group_label>
    <other_name>Roxicodone</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy adult volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers, greater than 50 kg, able and willing to sign informed consent

        Exclusion Criteria:

          -  Evidence of significant illness, condition affecting drug absorption, history of
             sleep apnea, and allergy to opioid drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4531007&amp;StudyName=A%20Randomized%2C%20Two-way%2C%20Crossover%20Study%20to%20Estimate%20the%20Relative%20Bioavailability%20of%20%20a%20Controlled-release%20Formulation%20of%20Oxycodone%20%2840%</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 22, 2012</lastchanged_date>
  <firstreceived_date>August 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Healthy Volunteers</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
